Cornercap Investment Counsel’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Cornercap Investment Counsel’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-71,046	Closed	-$107K	–	696
2023 Q1	$107K	Buy	71,046 +3,011	+4%	+$4.05K	0.02%	535
2022 Q4	$68K	Hold	68,035	–	–	0.01%	541
2022 Q3	$122K	Buy	68,035 +20,583	+43%	+$59.7K	0.02%	521
2022 Q2	$138K	Buy	+47,452	New	+$117K	0.02%	514

Cornercap Investment Counsel's TCRR Position: Q2 2023 in Review

Cornercap Investment Counsel sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 71,046 shares — an estimated $107K sold.

Cornercap Investment Counsel first reported a position in TCRR in Q2 2022 and held it in 4 quarters. The position peaked at $138K in Q2 2022. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

Cornercap Investment Counsel reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Cornercap Investment Counsel sold 71,046 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $107K.
Cornercap Investment Counsel first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2022 and held it in 4 quarters.
Cornercap Investment Counsel's TCR2 Therapeutics Inc. Common Stock position peaked at $138K in Q2 2022.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Cornercap Investment Counsel's 13F filing for Q2 2023, filed 11 Aug 2023.